Nanoform completes share issue
Helsinki-based nanoparticle medicine specialist Nanoform has completed a new share issue, in the process raising about €25 million from global and Nordic institutional investors. This will mainly be used to build a GMP manufacturing site in the US, where most of the company’s customers are.
The company said that it “continues to be committed to the strong execution of its communicated strategy”, having reached all its near-term targets for 2021 and being on track to deliver on its targets for 2022. The funding from an IPO it did in 2020 and the new share issue were said to be “sufficient for the growth strategy” it has outlined.
RELATED ARTICLES
Swiss CDMO Siegfried has inaugurated its new global R&D centre for drug substances at its site in Evionnaz.
Peptides CDMO AmbioPharm, has broken ground on a 650 m2, $28 million expansion project at its Shanghai manufacturing site. This is due to be complete in 2H 2025 and will produce over 8 tonnes/year of crude peptide.
Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China.
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
At CPHI in Milan in October, eight Indian CDMOs announced that they have formed a trade group to raise the profile of India’s drug services sector and make it a destination of choice.
